On October 23, 2018 CEL-SCI Corporation (NYSE American: CVM) reported it has received just under $8 million through the exercise of warrants to purchase shares of the Company’s common stock during the past 3 months (Press release, Cel-Sci, OCT 23, 2018, View Source [SID1234530605]). As of October 22, 2018, CEL-SCI had 28,271,615 outstanding shares of common stock.

"We have raised $20 million this year as we are nearing the date for the final data readout on our pivotal, global Phase 3 study in head and neck cancer," stated CEL-SCI’s Chief Executive Officer Geert Kersten

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!